Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

Fan Zhang,1 Tianmei Si,2,3 Chiun-Fang Chiou,4 Anthony WF Harris,5 Chang Yoon Kim,6 Padmashree Jahagirdar,7 Steve Ascher8 1Xian Janssen Pharmaceuticals, Beijing, People’s Republic of China; 2Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Beijing, P...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang F, Si T, Chiou CF, Harris AWF, Kim CY, Jahagirdar P, Ascher S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c4f7c99c20f64a76bfe01849b0f32994
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c4f7c99c20f64a76bfe01849b0f32994
record_format	dspace
spelling	oai:doaj.org-article:c4f7c99c20f64a76bfe01849b0f329942021-12-02T01:10:02ZEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia1178-2021https://doaj.org/article/c4f7c99c20f64a76bfe01849b0f329942015-03-01T00:00:00Zhttp://www.dovepress.com/efficacy-safety-and-impact-on-hospitalizations-of-paliperidone-palmita-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Fan Zhang,1 Tianmei Si,2,3 Chiun-Fang Chiou,4 Anthony WF Harris,5 Chang Yoon Kim,6 Padmashree Jahagirdar,7 Steve Ascher8 1Xian Janssen Pharmaceuticals, Beijing, People’s Republic of China; 2Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Beijing, People’s Republic of China; 3Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People’s Republic of China; 4Janssen Asia-Pacific, Singapore; 5Discipline of Psychiatry, Sydney Medical School, University of Sydney, Australia and Brian Dynamics Center, Westmead Millennium Institute for Medical Research, Westmead, NSW, Australia; 6Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; 7Theorem Clinical Research, Bangalore, India; 8Janssen Research and Development, LLC, Titusville, NJ, USA Objective: To evaluate the efficacy, safety, and impact on hospitalizations of long-acting injectable paliperidone palmitate (PP) treatment, in patients with recent-onset schizophrenia who had not responded satisfactorily to oral antipsychotics.Methods: In this 18-month, open-label, Phase-IIIb study from Asia-Pacific region, patients (18–50 years) with recent-onset (≤5 years) schizophrenia unsatisfactorily treated with previous oral antipsychotics were initiated on PP 150 mg eq on day 1, 100 mg eq on day 8, followed by flexible once monthly maintenance doses of 50–150 mg eq. The number and duration of hospitalizations were compared using a mirror analysis method between two periods: retrospective (12 months before PP initiation) and prospective (12 and 18 months after PP treatment) periods.Results: A total of 303 out of 521 (58%) patients (mean age, 28.7 years; 65.5% men, 92.5% Asian) completed the study. Positive and Negative Syndrome Scale (PANSS) total score improved significantly from baseline to month 18 (mean [standard deviation, SD] change: -11.3 [21.38], P<0.0001, primary endpoint). Subgroup analysis revealed greater improvements among patients with worse disease severity at baseline: PANSS ≥70 versus <70 (mean [SD] change: -23.1 [24.62] vs -4.7 [15.98], P<0.0001 each). Secondary efficacy endpoints such as Clinical Global Impression of Schizophrenia (CGI-SCH), Medication Satisfaction Questionnaire (MSQ) scores showed significant improvements (P<0.0001) from baseline; 33.3% patients achieved symptom remission. In mirror analyses set (N=474), PP significantly (P<0.0001) reduced mean number of hospitalization days/person/year (12-month: 74.3 vs 19.7; 18-month: 74.3 vs 18.9) as well as percentage of patients requiring hospitalization in past 12 months (12-month: 39.7% vs 24.6%; 18-month: 39.7% vs 25%), and PP treatment increased the proportion of patients not requiring hospitalization (12-month: 60.3% vs 75.4%; 18-month: 60.3% vs 75%) from retrospective to prospective period. Adverse events (≥15%) were extrapyramidal symptoms-related (31.3%), injection-site pain (18.6%), and insomnia (15.2%).Conclusion: PP was efficacious and generally tolerable with significant reductions observed in both number of hospitalizations and days spent in hospital.Trial registration number: ClinicalTrials.gov: NCT01051531. Keywords: atypical antipsychotics, long-acting injectables, open-label, paliperidone palmitate, schizophreniaZhang FSi TChiou CFHarris AWFKim CYJahagirdar PAscher SDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 657-668 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Zhang F Si T Chiou CF Harris AWF Kim CY Jahagirdar P Ascher S Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
description	Fan Zhang,1 Tianmei Si,2,3 Chiun-Fang Chiou,4 Anthony WF Harris,5 Chang Yoon Kim,6 Padmashree Jahagirdar,7 Steve Ascher8 1Xian Janssen Pharmaceuticals, Beijing, People’s Republic of China; 2Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Beijing, People’s Republic of China; 3Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, People’s Republic of China; 4Janssen Asia-Pacific, Singapore; 5Discipline of Psychiatry, Sydney Medical School, University of Sydney, Australia and Brian Dynamics Center, Westmead Millennium Institute for Medical Research, Westmead, NSW, Australia; 6Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; 7Theorem Clinical Research, Bangalore, India; 8Janssen Research and Development, LLC, Titusville, NJ, USA Objective: To evaluate the efficacy, safety, and impact on hospitalizations of long-acting injectable paliperidone palmitate (PP) treatment, in patients with recent-onset schizophrenia who had not responded satisfactorily to oral antipsychotics.Methods: In this 18-month, open-label, Phase-IIIb study from Asia-Pacific region, patients (18–50 years) with recent-onset (≤5 years) schizophrenia unsatisfactorily treated with previous oral antipsychotics were initiated on PP 150 mg eq on day 1, 100 mg eq on day 8, followed by flexible once monthly maintenance doses of 50–150 mg eq. The number and duration of hospitalizations were compared using a mirror analysis method between two periods: retrospective (12 months before PP initiation) and prospective (12 and 18 months after PP treatment) periods.Results: A total of 303 out of 521 (58%) patients (mean age, 28.7 years; 65.5% men, 92.5% Asian) completed the study. Positive and Negative Syndrome Scale (PANSS) total score improved significantly from baseline to month 18 (mean [standard deviation, SD] change: -11.3 [21.38], P<0.0001, primary endpoint). Subgroup analysis revealed greater improvements among patients with worse disease severity at baseline: PANSS ≥70 versus <70 (mean [SD] change: -23.1 [24.62] vs -4.7 [15.98], P<0.0001 each). Secondary efficacy endpoints such as Clinical Global Impression of Schizophrenia (CGI-SCH), Medication Satisfaction Questionnaire (MSQ) scores showed significant improvements (P<0.0001) from baseline; 33.3% patients achieved symptom remission. In mirror analyses set (N=474), PP significantly (P<0.0001) reduced mean number of hospitalization days/person/year (12-month: 74.3 vs 19.7; 18-month: 74.3 vs 18.9) as well as percentage of patients requiring hospitalization in past 12 months (12-month: 39.7% vs 24.6%; 18-month: 39.7% vs 25%), and PP treatment increased the proportion of patients not requiring hospitalization (12-month: 60.3% vs 75.4%; 18-month: 60.3% vs 75%) from retrospective to prospective period. Adverse events (≥15%) were extrapyramidal symptoms-related (31.3%), injection-site pain (18.6%), and insomnia (15.2%).Conclusion: PP was efficacious and generally tolerable with significant reductions observed in both number of hospitalizations and days spent in hospital.Trial registration number: ClinicalTrials.gov: NCT01051531. Keywords: atypical antipsychotics, long-acting injectables, open-label, paliperidone palmitate, schizophrenia
format	article
author	Zhang F Si T Chiou CF Harris AWF Kim CY Jahagirdar P Ascher S
author_facet	Zhang F Si T Chiou CF Harris AWF Kim CY Jahagirdar P Ascher S
author_sort	Zhang F
title	Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
title_short	Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
title_full	Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
title_fullStr	Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
title_full_unstemmed	Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
title_sort	efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/c4f7c99c20f64a76bfe01849b0f32994
work_keys_str_mv	AT zhangf efficacysafetyandimpactonhospitalizationsofpaliperidonepalmitateinrecentonsetschizophrenia AT sit efficacysafetyandimpactonhospitalizationsofpaliperidonepalmitateinrecentonsetschizophrenia AT chioucf efficacysafetyandimpactonhospitalizationsofpaliperidonepalmitateinrecentonsetschizophrenia AT harrisawf efficacysafetyandimpactonhospitalizationsofpaliperidonepalmitateinrecentonsetschizophrenia AT kimcy efficacysafetyandimpactonhospitalizationsofpaliperidonepalmitateinrecentonsetschizophrenia AT jahagirdarp efficacysafetyandimpactonhospitalizationsofpaliperidonepalmitateinrecentonsetschizophrenia AT aschers efficacysafetyandimpactonhospitalizationsofpaliperidonepalmitateinrecentonsetschizophrenia
_version_	1718403282970345472

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

Ejemplares similares